Key facts
- Therna Biosciences’s last known valuation is $23.1M (Aug 2025).
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Aug 2025.
- Notable investors include Pear (California), AIX Ventures, Fusion Fund.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Therna Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Therna Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Therna Biosciences
Developer of AI-driven RNA design technology designed for therapeutic research and development purposes. The company integrates computational modeling with experimental validation to generate, evaluate, and refine RNA sequences based on biological signal interpretation, sequence-structure relationships, expression control, stability tuning, and immune interaction avoidance, enabling biotechnology and pharmaceutical researchers to design, test, and optimize RNA-based medicines with predictability, functional control, and reduced experimental iteration.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2023
- Website
- therna.com/
- Ownership
- Privately Held (backing)
Therna Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Therna Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Therna Biosciences in its N-PORT filings yet. We sweep new filings monthly.